Document Detail

The risks and benefits of drug-eluting stents in the setting of STEMI.
MedLine Citation:
PMID:  18715537     Owner:  NLM     Status:  MEDLINE    
Primary percutaneous coronary intervention (PCI) represents the treatment of choice in patients with ST-segment elevation myocardial infarction (STEMI). In randomized trials excluding STEMI patients, using drug-eluting stents (DES) significantly reduced angiographic restenosis and target vessel revascularization compared with bare metal stents (BMS); however, concerns exist regarding an increased follow-up incidence of stent thrombosis after DES implantation. This complication, which is associated with higher mortality and morbidity rates, may be more frequent among STEMI patients receiving DES versus BMS. Various registries, randomized trials, and two recent meta-analyses on patients undergoing primary PCI have shown that using DES is safe and is associated with significantly reduced rates of restenosis and repeat intervention without an increased risk of myocardial infarction or stent thrombosis at intermediate-term follow-up. However, large trials with hard clinical end points and longer follow-up are needed before routine DES use can be recommended in patients undergoing primary PCI.
Rosetta Melfi; Annunziata Nusca; Giuseppe Patti; Germano Di Sciascio
Related Documents :
17493467 - Serial intravascular ultrasonic study of outcomes of coronary culprit lesions with plaq...
21288097 - Myocardial infarction due to percutaneous coronary intervention.
11961147 - Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts.
1954687 - Restenosis following coronary angioplasty.
22771877 - Repaired tetralogy of fallot: ratio of right ventricular volume to left ventricular vol...
15519017 - A hard look at angiotensin receptor blockers in heart failure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  10     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-08-21     Completed Date:  2008-12-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  402-6     Citation Subset:  IM    
Department of Cardiovascular Sciences, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Drug-Eluting Stents* / adverse effects
Meta-Analysis as Topic
Myocardial Infarction / therapy*
Randomized Controlled Trials as Topic
Thrombosis / etiology
Time Factors
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Putting the benefits of percutaneous coronary revascularization into perspective: from trials to gui...
Next Document:  Percutaneous coronary intervention without onsite surgical backup.